Study on the relationship between long-term oral anti hepatitis B nucleoside (acid) analogues and hepatic steatosis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061728

Enrollment

Unknown

Registered

2022-07-01

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

ETV group:Nil

TDF group:Nil

TAF group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patients with chronic hepatitis B who were diagnosed as the first treatment of chronic hepatitis B according to the guidelines for the prevention and treatment of chronic hepatitis B (2019 Edition); 2. 18-80 years old.

Exclusion criteria

Exclusion criteria: 1. alcohol consumption > 30 g / day; 2. receiving lipogenic drugs, including corticosteroids, antiarrhythmic drugs, anticancer drugs and methotrexate; 3. infection with hepatitis A, C, D or E virus and human immunodeficiency virus; 4. other liver diseases, including autoimmune liver disease, drug-induced liver injury and hereditary metabolic liver disease; 5. Severe liver disease (decompensated cirrhosis or HCC).

Design outcomes

Secondary

Measure	Time frame
routine blood tests;renal function;	—

Primary

Measure	Time frame
Hepatic function;blood lipids;BMI;waist circumference;CAP;	—

Countries

China

Contacts

Public ContactDazhi Zhang

The Second Affiliated Hospital of Chongqing Medical University

dzhzhang@yahoo.com+86 13452382818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026